Article Details
Retrieved on: 2020-12-06 14:26:15
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Not so for <b>Roche's</b> cevostamab (RG6160), an anti-FcRH5 bispecific whose phase I trial has now treated 53 subjects. Five of eight who had progressed ...
Article found on: www.evaluate.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here